$KNSA
Kiniksa Pharmaceuticals Ltd

2021 Q2 Form 10-Q Financial Statement

#000155837021010581 Filed on August 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $7.704M $0.00
YoY Change
Cost Of Revenue $2.466M
YoY Change
Gross Profit $5.238M
YoY Change
Gross Profit Margin 67.99%
Selling, General & Admin $21.85M $9.536M
YoY Change 129.11% 12.99%
% of Gross Profit 417.11%
Research & Development $23.95M $22.32M
YoY Change 7.26% -27.63%
% of Gross Profit 457.14%
Depreciation & Amortization $416.0K $595.0K
YoY Change -30.08% 17.13%
% of Gross Profit 7.94%
Operating Expenses $45.79M $31.86M
YoY Change 43.73% -18.91%
Operating Profit -$40.56M -$31.86M
YoY Change 27.29% -18.91%
Interest Expense $6.000K $270.0K
YoY Change -97.78% -84.3%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$40.55M -$31.59M
YoY Change 28.34% -15.9%
Income Tax $1.014M $5.875M
% Of Pretax Income
Net Earnings -$41.56M -$37.47M
YoY Change 10.93% 0.75%
Net Earnings / Revenue -539.5%
Basic Earnings Per Share -$0.61
Diluted Earnings Per Share -$0.61 -$647.0K
COMMON SHARES
Basic Shares Outstanding 68.40M
Diluted Shares Outstanding 68.40M

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $225.9M $252.4M
YoY Change -10.51% -12.18%
Cash & Equivalents $168.0M $123.5M
Short-Term Investments $57.91M $128.9M
Other Short-Term Assets $10.01M $12.10M
YoY Change -17.26% 34.44%
Inventory $6.381M
Prepaid Expenses
Receivables $2.551M
Other Receivables $0.00
Total Short-Term Assets $244.8M $264.5M
YoY Change -7.44% -10.79%
LONG-TERM ASSETS
Property, Plant & Equipment $3.449M $5.210M
YoY Change -33.8% -41.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.813M $400.0K
YoY Change 1353.25% -85.71%
Total Long-Term Assets $34.40M $6.948M
YoY Change 395.08% -40.1%
TOTAL ASSETS
Total Short-Term Assets $244.8M $264.5M
Total Long-Term Assets $34.40M $6.948M
Total Assets $279.2M $271.4M
YoY Change 2.86% -11.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.156M $2.373M
YoY Change 75.14% -74.48%
Accrued Expenses $31.06M $16.50M
YoY Change 88.28% -20.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $38.78M $20.55M
YoY Change 88.7% -31.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.141M $334.0K
YoY Change 241.62% -88.07%
Total Long-Term Liabilities $1.141M $334.0K
YoY Change 241.62% -88.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $38.78M $20.55M
Total Long-Term Liabilities $1.141M $334.0K
Total Liabilities $43.42M $21.03M
YoY Change 106.53% -36.09%
SHAREHOLDERS EQUITY
Retained Earnings -$608.5M -$420.0M
YoY Change 44.89%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $235.8M $250.4M
YoY Change
Total Liabilities & Shareholders Equity $279.2M $271.4M
YoY Change 2.86% -11.9%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$41.56M -$37.47M
YoY Change 10.93% 0.75%
Depreciation, Depletion And Amortization $416.0K $595.0K
YoY Change -30.08% 17.13%
Cash From Operating Activities -$38.79M -$29.22M
YoY Change 32.73% -29.88%
INVESTING ACTIVITIES
Capital Expenditures -$63.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $86.05M -$31.21M
YoY Change -375.71% -176.93%
Cash From Investing Activities $86.00M -$31.22M
YoY Change -375.45% -175.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 883.0K 77.57M
YoY Change -98.86% 15730.61%
NET CHANGE
Cash From Operating Activities -38.79M -29.22M
Cash From Investing Activities 86.00M -31.22M
Cash From Financing Activities 883.0K 77.57M
Net Change In Cash 48.10M 17.13M
YoY Change 180.76% 8915.79%
FREE CASH FLOW
Cash From Operating Activities -$38.79M -$29.22M
Capital Expenditures -$63.00K $0.00
Free Cash Flow -$38.72M -$29.22M
YoY Change 32.52% -31.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q2 knsa Fair Value Assets Level1 To Level3 Transfers Amount
FairValueAssetsLevel1ToLevel3TransfersAmount
0
CY2020Q4 knsa Fair Value Assets Level1 To Level3 Transfers Amount
FairValueAssetsLevel1ToLevel3TransfersAmount
0
CY2021Q2 knsa Fair Value Assets Level2 To Level3 Transfers Amount
FairValueAssetsLevel2ToLevel3TransfersAmount
0
CY2020Q4 knsa Fair Value Assets Level2 To Level3 Transfers Amount
FairValueAssetsLevel2ToLevel3TransfersAmount
0
CY2021Q2 knsa Fair Value Assets Level3 To Level1 Transfers Amount
FairValueAssetsLevel3ToLevel1TransfersAmount
0
CY2020Q4 knsa Fair Value Assets Level3 To Level1 Transfers Amount
FairValueAssetsLevel3ToLevel1TransfersAmount
0
CY2021Q2 knsa Fair Value Assets Level3 To Level2 Transfers Amount
FairValueAssetsLevel3ToLevel2TransfersAmount
0
CY2020Q4 knsa Fair Value Assets Level3 To Level2 Transfers Amount
FairValueAssetsLevel3ToLevel2TransfersAmount
0
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2021Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2021Q2 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2021Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2020Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2021Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
dei Entity Central Index Key
EntityCentralIndexKey
0001730430
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38492
dei Entity Registrant Name
EntityRegistrantName
Kiniksa Pharmaceuticals, Ltd.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
D0
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1327726
dei Entity Address Address Line1
EntityAddressAddressLine1
Clarendon House
dei Entity Address Address Line2
EntityAddressAddressLine2
2 Church Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Hamilton
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
HM11
dei Entity Address Country
EntityAddressCountry
BM
dei City Area Code
CityAreaCode
808
dei Local Phone Number
LocalPhoneNumber
451-3453
dei Security12b Title
Security12bTitle
Class A Common Shares
dei Trading Symbol
TradingSymbol
KNSA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
167953000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114038000
CY2021Q2 us-gaap Short Term Investments
ShortTermInvestments
57913000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2466000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23945000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22324000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52628000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43225000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
209444000
CY2021Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
210000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
210000
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2551000
CY2021Q2 us-gaap Inventory Net
InventoryNet
6381000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9802000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9557000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
244810000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
333249000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3449000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4051000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5386000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6566000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5813000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5588000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
19750000
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
10000
CY2021Q2 us-gaap Assets
Assets
279208000
CY2020Q4 us-gaap Assets
Assets
349464000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4156000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
503000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31064000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
29199000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2636000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2107000
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
926000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
37000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
38782000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31846000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3500000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4878000
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1141000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
805000
CY2021Q2 us-gaap Liabilities
Liabilities
43423000
CY2020Q4 us-gaap Liabilities
Liabilities
37529000
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
844260000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
829424000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
27000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-34000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-608520000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-517473000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
235785000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
311935000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
279208000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
349464000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7704000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7704000
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2466000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-37469000
us-gaap Net Income Loss
NetIncomeLoss
-91047000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3696000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-41563000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21848000
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9536000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
42448000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18022000
CY2021Q2 knsa Total Cost Of Revenue And Operating Expenses
TotalCostOfRevenueAndOperatingExpenses
48259000
CY2020Q2 knsa Total Cost Of Revenue And Operating Expenses
TotalCostOfRevenueAndOperatingExpenses
31860000
knsa Total Cost Of Revenue And Operating Expenses
TotalCostOfRevenueAndOperatingExpenses
97542000
knsa Total Cost Of Revenue And Operating Expenses
TotalCostOfRevenueAndOperatingExpenses
61247000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-40555000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-31860000
us-gaap Operating Income Loss
OperatingIncomeLoss
-89838000
us-gaap Operating Income Loss
OperatingIncomeLoss
-61247000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
6000
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
266000
us-gaap Investment Income Interest
InvestmentIncomeInterest
15000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1055000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40549000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31594000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-89823000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-60192000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1014000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5875000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1224000
us-gaap Net Income Loss
NetIncomeLoss
-63888000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.33
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.13
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68395703
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
57914105
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68332943
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
56618397
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-41563000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-37469000
us-gaap Net Income Loss
NetIncomeLoss
-91047000
us-gaap Net Income Loss
NetIncomeLoss
-63888000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
48000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-231000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
61000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-24000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
48000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-231000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
61000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-24000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41515000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37700000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-90986000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63912000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
311935000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
1106000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7126000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
13000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-49484000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
270696000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
887000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5717000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
48000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-41563000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
235785000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
225423000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2414000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4209000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
207000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-26419000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
205834000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2936000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4851000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-231000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-37469000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
250416000
us-gaap Profit Loss
ProfitLoss
-91047000
us-gaap Profit Loss
ProfitLoss
-63888000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1029000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1189000
us-gaap Share Based Compensation
ShareBasedCompensation
12843000
us-gaap Share Based Compensation
ShareBasedCompensation
9060000
knsa Noncash Lease Expense
NoncashLeaseExpense
1193000
knsa Noncash Lease Expense
NoncashLeaseExpense
603000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-603000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
313000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
4372000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
196000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3843000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2551000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6381000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
279000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3654000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3228000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2753000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4146000
knsa Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-863000
knsa Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-833000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
337000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
7000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
76528000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114248000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47138000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78905000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-61020000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
113000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
223000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
97460000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
133954000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
248400000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
191750000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
20000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
130827000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
57573000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
47600000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
27594000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
569000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1993000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
5350000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1993000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
79975000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
53915000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
168163000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
123666000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
854000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
282000
knsa Deferred Offering Costs Included In Accrued Expenses And Accounts Payable
DeferredOfferingCostsIncludedInAccruedExpensesAndAccountsPayable
335000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the recognition of revenue, the capitalization of inventory, the accrual for research and development expenses and the valuation of share-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</p>
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-608520000
us-gaap Net Income Loss
NetIncomeLoss
-91047000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78905000
knsa Contractual Obligation Regulatory Milestone Paid
ContractualObligationRegulatoryMilestonePaid
20000000
CY2021Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
225866000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and short-term investments. At June 30, 2021 and December 31, 2020, substantially all of the Company’s cash, cash equivalents and short-term investments were held at two financial institutions. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash, cash equivalents and short-term investments and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also subject to credit risk from the accounts receivable related to product revenue. Trade accounts receivable are recorded net of allowances for cash discounts associated to prompt payments from customers. All trade accounts receivable arise from product revenue in the United States due from the Company’s third party logistics provider. There were no material write-offs charged against the allowance for the six months ended June 30, 2021.</p>
CY2021Q2 us-gaap Cash Collateral For Borrowed Securities
CashCollateralForBorrowedSecurities
210000
CY2020Q4 us-gaap Cash Collateral For Borrowed Securities
CashCollateralForBorrowedSecurities
210000
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
20000000
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P20Y
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2020Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2021Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2020Q2 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2021Q2 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2020Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2020Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2021Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2021Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2021Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
knsa Number Of Securities Unrealized Loss Position
NumberOfSecuritiesUnrealizedLossPosition
6
CY2021Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
34097000
CY2020 knsa Number Of Securities Unrealized Loss Position
NumberOfSecuritiesUnrealizedLossPosition
17
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
107753000
CY2021Q2 knsa Product Revenue Reserves And Allowances
ProductRevenueReservesAndAllowances
1114000
knsa Product Revenue Provision For Specific Product Returns
ProductRevenueProvisionForSpecificProductReturns
236000
CY2021Q2 knsa Product Revenue Reserves And Allowances
ProductRevenueReservesAndAllowances
1114000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7704000
knsa Product Revenue Provision For Contractual Adjustments
ProductRevenueProvisionForContractualAdjustments
787000
knsa Product Revenue Provision For Government Rebates
ProductRevenueProvisionForGovernmentRebates
288000
knsa Product Revenue Provision For Product Returns
ProductRevenueProvisionForProductReturns
281000
knsa Product Revenue Provision For Reserves And Allowances
ProductRevenueProvisionForReservesAndAllowances
1356000
knsa Product Revenue Refunds On Contractual Adjustments
ProductRevenueRefundsOnContractualAdjustments
242000
knsa Product Revenue Refunds And Credits For Reserves And Allowances
ProductRevenueRefundsAndCreditsForReservesAndAllowances
242000
CY2021Q2 knsa Product Revenue Reserve For Contractual Adjustments
ProductRevenueReserveForContractualAdjustments
545000
CY2021Q2 knsa Product Revenue Reserve For Government Rebates
ProductRevenueReserveForGovernmentRebates
288000
CY2021Q2 knsa Product Revenue Reserve For Sales Returns
ProductRevenueReserveForSalesReturns
281000
CY2020Q4 us-gaap Inventory Net
InventoryNet
0
CY2021Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
4165000
CY2021Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2216000
CY2021Q2 us-gaap Inventory Net
InventoryNet
6381000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5436000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8781000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8885000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4730000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3449000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4051000
CY2021Q2 us-gaap Depreciation
Depreciation
416000
CY2020Q2 us-gaap Depreciation
Depreciation
595000
us-gaap Depreciation
Depreciation
706000
us-gaap Depreciation
Depreciation
1189000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0
CY2021Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
20000000
CY2021Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
250000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
19750000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
500000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1000000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1000000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1000000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1000000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1000000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
14250000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
19750000
CY2021Q2 knsa Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
20541000
CY2020Q4 knsa Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
16945000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7892000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7704000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2272000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3988000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
359000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
562000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31064000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
29199000
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0107
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0039
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0101
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0071
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M25D
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M26D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y25D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M4D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7599
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7938
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7692
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7971
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5717000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4851000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12843000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9060000
CY2021Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
20000000
CY2021Q2 us-gaap Inventory Net
InventoryNet
6381000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-41563000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-37469000
us-gaap Net Income Loss
NetIncomeLoss
-91047000
us-gaap Net Income Loss
NetIncomeLoss
-63888000
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68395703
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
57914105
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68332943
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
56618397
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.33
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.13
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9944017
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8970107
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2020Q2 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2021Q2 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2020Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2020Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2021Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2020Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2021Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2021Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2021Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1014000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1224000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5875000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3696000
CY2021Q2 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
36551000
CY2021Q2 knsa Purchase Commitment Obligation Due In Next Rolling Twelve Months
PurchaseCommitmentObligationDueInNextRollingTwelveMonths
16957000

Files In Submission

Name View Source Status
0001558370-21-010581-index-headers.html Edgar Link pending
0001558370-21-010581-index.html Edgar Link pending
0001558370-21-010581.txt Edgar Link pending
0001558370-21-010581-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
knsa-20210630.xsd Edgar Link pending
knsa-20210630x10q.htm Edgar Link pending
knsa-20210630x10q_htm.xml Edgar Link completed
knsa-20210630xex31d1.htm Edgar Link pending
knsa-20210630xex31d2.htm Edgar Link pending
knsa-20210630xex32d1.htm Edgar Link pending
knsa-20210630xex32d2.htm Edgar Link pending
knsa-20210630_cal.xml Edgar Link unprocessable
knsa-20210630_def.xml Edgar Link unprocessable
knsa-20210630_lab.xml Edgar Link unprocessable
knsa-20210630_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending